AB Science’s AB8939 Shows 67% Response Rate in Relapsed AML Trial
Event summary
- AB Science completed Step 3 of Phase 1 trial evaluating AB8939 + venetoclax in refractory/relapsed AML, achieving a 67% overall response rate and 100% disease control rate.
- No dose-limiting toxicities observed across two dose levels (16 mg/m² and 21.3 mg/m²) of AB8939 combined with venetoclax.
- Trial included six heavily pre-treated patients with adverse genetic profiles, including TP53 mutations and complex karyotypes.
- Next steps include evaluating a triple combination of AB8939 + venetoclax + azacitidine in Step 4.
The big picture
AB Science’s Phase 1 trial results position AB8939 as a potential breakthrough for treating high-risk AML patients with adverse genetics, where standard therapies often fail. The combination of AB8939 and venetoclax demonstrated strong efficacy without dose-limiting toxicities, addressing a critical unmet need in oncology. The next phase will evaluate a triple combination, potentially expanding the drug’s reach in a market dominated by high treatment costs and poor prognosis for relapsed patients.
What we're watching
- Clinical Development
- Whether the triple combination of AB8939 + venetoclax + azacitidine can further improve efficacy in high-risk AML patients.
- Regulatory Strategy
- How discussions with EMA and FDA on potential registration pathways will shape AB Science’s next steps.
- Market Potential
- The pace at which AB8939 can capture share in the EUR 2 billion relapsed/refractory AML market.
Related topics